Abiopharma

🔍 Ball Robert Joseph (Director)

Company: SHOULDER INNOVATIONS, INC. (SI)

Report Date: 2026-09-14

Detailed Transactions and Holdings:

• Acquired 89,233 shares of Common Stock at $2.0988 per share (Direct)
  Date: 2026-09-14 | Code: M | equity_swap_involved: 0 | shares_owned_after: 390,999.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 10,175 shares of Common Stock at $18.4478 per share (Direct)
  Date: 2026-09-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 380,824.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 89,233 shares of Stock Option at $2.0988 per share (Derivative)
  Date: 2026-09-14 | Code: M | Expires: 2030-12-16 | equity_swap_involved: 0 | shares_owned_after: 92,143.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Includes 1,748 shares of Common Stock acquired on June 30, 2026 pursuant to the Issuer's 2025 Employee Stock Purchase Plan.
• F2: The price reported in Column 4 is a weighted average sale price. The shares of Common Stock were sold in multiple transactions at prices ranging from $18.22 to $18.63, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities & Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares of Common Stock sold at each separate price within the range set forth herein. The shares of Common Stock were sold solely to cover the exercise price in connection with the exercise of the stock option.
• F3: The stock option is fully vested and currently exercisable.